TOKYO, Mar 27 (Pulse News Wire) – HEALIOS K.K. (4593.T) announced today that it has received formal approval for a grant worth approximately ¥7 billion from the Ministry of Economy, Trade and Industry's supplementary budget for fiscal year 2025.
The funding supports the construction of a manufacturing facility for regenerative medicine products within DP-Lab Kobe operated by Yamada House Co., Ltd. The Cell Processing Center (CPC) is scheduled to begin operations in January 2028 and will focus on developing and manufacturing cell therapies such as ARDS treatment HLCM051. This initiative aligns with government efforts to advance next-generation manufacturing infrastructure.
HEALIOS plans to integrate world-class three-dimensional large-scale cultivation technology and AI process development, optimize quality and costs through automation and closed-system platforms, and support clients from early-stage development to commercial production. The company also aims to establish a global export-oriented contract development and manufacturing organization (CDMO) service. Looking ahead, related expenses and revenue from the grant will primarily be recorded as research and development expenditures and other income.
HEALIOS began work on targeted equipment investments and process development in the fiscal year ending December 2025 and will promptly disclose any impact on its fiscal year 2026 performance once determined.
🟢 Confidence: High AI-translated content.